Terms: = Prostate cancer AND NF2, ACN, 4771, ENSG00000186575, P35240, SCH, Merlin, BANF AND Treatment
17 results:
1. Lysine Demethylase 6B Regulates prostate cancer Cell Proliferation by Controlling c-MYC Expression.
Yıldırım-Buharalıoğlu G
Mol Pharmacol; 2022 Feb; 101(2):106-119. PubMed ID: 34862309
[TBL] [Abstract] [Full Text] [Related]
2. Subclinical hypothyroidism and the risk of cancer incidence and cancer mortality: a systematic review.
Gómez-Izquierdo J; Filion KB; Boivin JF; Azoulay L; Pollak M; Yu OHY
BMC Endocr Disord; 2020 Jun; 20(1):83. PubMed ID: 32517676
[TBL] [Abstract] [Full Text] [Related]
3. Inhibitory effects of schisandrin B on human prostate cancer cells.
Nasser MI; Han T; Adlat S; Tian Y; Jiang N
Oncol Rep; 2019 Jan; 41(1):677-685. PubMed ID: 30320364
[TBL] [Abstract] [Full Text] [Related]
4. Elevated expression of Par3 promotes prostate cancer metastasis by forming a Par3/aPKC/KIBRA complex and inactivating the hippo pathway.
Zhou PJ; Xue W; Peng J; Wang Y; Wei L; Yang Z; Zhu HH; Fang YX; Gao WQ
J Exp Clin Cancer Res; 2017 Oct; 36(1):139. PubMed ID: 29017577
[TBL] [Abstract] [Full Text] [Related]
5. Two novel peptides derived from Sinonovacula constricta inhibit the proliferation and induce apoptosis of human prostate cancer cells.
Huang F; Ding G; Yang Z; Yu F
Mol Med Rep; 2017 Nov; 16(5):6697-6707. PubMed ID: 28901516
[TBL] [Abstract] [Full Text] [Related]
6. Mortality Among Men with Advanced prostate cancer Excluded from the ProtecT Trial.
Johnston TJ; Shaw GL; Lamb AD; Parashar D; Greenberg D; Xiong T; Edwards AL; Gnanapragasam V; Holding P; Herbert P; Davis M; Mizielinsk E; Lane JA; Oxley J; Robinson M; Mason M; Staffurth J; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Kockelbergh R; Kynaston H; Prescott S; Paul A; Powell P; Rosario D; Rowe E; Donovan JL; Hamdy FC; Neal DE;
Eur Urol; 2017 Mar; 71(3):381-388. PubMed ID: 27720537
[TBL] [Abstract] [Full Text] [Related]
7. Role of merlin/nf2 inactivation in tumor biology.
Petrilli AM; Fernández-Valle C
Oncogene; 2016 Feb; 35(5):537-48. PubMed ID: 25893302
[TBL] [Abstract] [Full Text] [Related]
8. Proteomic-based identification of multiple pathways underlying n-butylidenephthalide-induced apoptosis in LNCaP human prostate cancer cells.
Pang CY; Chiu SC; Harn HJ; Zhai WJ; Lin SZ; Yang HH
Food Chem Toxicol; 2013 Sep; 59():281-8. PubMed ID: 23770345
[TBL] [Abstract] [Full Text] [Related]
9. STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.
Day JM; Foster PA; Tutill HJ; Schmidlin F; Sharland CM; Hargrave JD; Vicker N; Potter BV; Reed MJ; Purohit A
Endocr Relat Cancer; 2013 Feb; 20(1):53-64. PubMed ID: 23132791
[TBL] [Abstract] [Full Text] [Related]
10. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract] [Full Text] [Related]
11. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine.
Hewish M; Chau I; Cunningham D
Recent Pat Anticancer Drug Discov; 2009 Jan; 4(1):54-72. PubMed ID: 19149688
[TBL] [Abstract] [Full Text] [Related]
12. Extraperitoneal laparoscopic radical prostatectomy. Results after 50 cases.
Bollens R; Vanden Bossche M; Roumeguere T; Damoun A; Ekane S; Hoffmann P; Zlotta AR; Schulman CC
Eur Urol; 2001 Jul; 40(1):65-9. PubMed ID: 11528178
[TBL] [Abstract] [Full Text] [Related]
13. DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology.
Labrie F; Luu-The V; Labrie C; Simard J
Front Neuroendocrinol; 2001 Jul; 22(3):185-212. PubMed ID: 11456468
[TBL] [Abstract] [Full Text] [Related]
14. Antitumor activity of sch 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.
Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Lipari P; Malkowski M; Ferrari E; Nielsen L; Prioli N; Dell J; Sinha D; Syed J; Korfmacher WA; Nomeir AA; Lin CC; Wang L; Taveras AG; Doll RJ; Njoroge FG; Mallams AK; Remiszewski S; Catino JJ; Girijavallabhan VM; Bishop WR
Cancer Res; 1998 Nov; 58(21):4947-56. PubMed ID: 9810004
[TBL] [Abstract] [Full Text] [Related]
15. Flutamide as primary treatment for metastatic prostatic cancer.
Lundgren R
Br J Urol; 1987 Feb; 59(2):156-8. PubMed ID: 3828712
[TBL] [Abstract] [Full Text] [Related]
16. Prostatic cancer and sch-13521: II. Histological alterations and the pituitary gonadal axis.
Prout GR; Irwin RJ; Kliman B; Daly JJ; MacLaughlin RA; Griffin PP
J Urol; 1975 Jun; 113(6):834-40. PubMed ID: 1152158
[TBL] [Abstract] [Full Text] [Related]
17. Chemotherapy of prostatic cancer.
Schmidt JD
Urol Clin North Am; 1975 Feb; 2(1):185-96. PubMed ID: 1093059
[TBL] [Abstract] [Full Text] [Related]
